Table 2.
Cumulative incidence rates of leiomyosarcoma.
| Leiomyosarcoma Tumour Grade pT1 | Leiomyosarcoma Tumour Grade >pT1 | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | p-Value 1 | 2-Year Cuminc |
5-Year Cuminc |
8-Year Cuminc |
p-Value 1 | 2-Year Cuminc |
5-Year Cuminc |
8-Year Cuminc |
| Local recurrence | ||||||||
| Morcellation | 0.001 | 0.5 | ||||||
| Non-morcellated LMS | 26% (18%, 34%) |
38% (29%, 47%) |
62% (43%, 76%) |
72% (52%, 85%) |
||||
| Morcellated LMS | 49% (38%, 59%) | 58% (47%, 68%) | 70% (49%, 84%) | 76% (52%, 89%) | ||||
| Distant metastases | ||||||||
| Morcellation | <0.001 | 0.14 | ||||||
| Non-morcellated LMS | 35% (26%, 44%) |
54% (44%, 63%) |
52% (33%, 68%) |
52% (33%, 68%) |
||||
| Morcellated LMS | 21% (13%, 30%) |
29% (20%, 39%) |
27% (12%, 46%) |
36% (14%, 59%) |
||||
| LMS death | ||||||||
| Overall | 18% (13%, 24%) |
37% (29%, 44%) |
47% (39%, 55%) |
45% (32%, 58%) |
71% (56%, 82%) |
81% (64%, 90%) |
||
| Morcellation | >0.9 | 0.2 | ||||||
| Non-morcellated LMS | 18% (12%, 26%) |
36% (27%, 45%) |
48% (36%, 59%) |
44% (27%, 60%) |
59% (39%, 74%) |
74% (50%, 88%) |
||
| Morcellated LMS | 19% (11%, 28%) |
37% (27%, 48%) |
46% (33%, 57%) |
47% (26%, 65%) |
88% (56%, 97%) |
88% 56%, 97%) |
||
1 Gray’s Test.